GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (XKAZ:PFE_KZ) » Definitions » Total Liabilities

Pfizer (XKAZ:PFE_KZ) Total Liabilities : $126,918 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pfizer Total Liabilities?

Pfizer's Total Liabilities for the quarter that ended in Sep. 2024 was $126,918 Mil.

Pfizer's quarterly Total Liabilities declined from Mar. 2024 ($128,537.00 Mil) to Jun. 2024 ($128,218.00 Mil) and declined from Jun. 2024 ($128,218.00 Mil) to Sep. 2024 ($126,918.00 Mil).

Pfizer's annual Total Liabilities declined from Dec. 2021 ($104,014.00 Mil) to Dec. 2022 ($101,289.00 Mil) but then increased from Dec. 2022 ($101,289.00 Mil) to Dec. 2023 ($137,213.00 Mil).


Pfizer Total Liabilities Historical Data

The historical data trend for Pfizer's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Total Liabilities Chart

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104,147.00 90,756.00 104,014.00 101,289.00 137,213.00

Pfizer Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 117,817.00 137,213.00 128,537.00 128,218.00 126,918.00

Pfizer Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pfizer's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=47794+(60499+26113
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+640+2167)
=137,213

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=226501-89288
=137,213

Pfizer's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=43211+(56918+22558
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+2158+2073)
=126,918

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=219476-92558
=126,918

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pfizer Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pfizer's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Headlines

No Headlines